King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Hanan Alkhaldi
Dr. Hanan Alkhaldi is a Consultant Adult Hematologist and Acute Leukemia specialist based in Riyadh, Saudi Arabia, with advanced training from the United States. A trusted acute leukemia specialist Riyadh, Saudi Arabia, she is active in CAR T-cell therapy, adult stem-cell transplantation, and Philadelphia-positive leukemia research.
- US-trained internist and hematologist-oncologist with international fellowship experience.
- Active role in the CD19 CAR T-cell therapy programme for adult B-ALL.
- Contributing author on multi-centre research in CAR-T, CML in pregnancy, and Ph-positive ALL.
- Regularly manages relapsed / refractory acute leukemia and primary mediastinal B-cell lymphoma.
- Cares for international patients seeking haploidentical transplantation and advanced cellular therapy.
Qualifications & Credentials
Medical Degrees
- MBBS
- Residency — Internal Medicine, University of Maryland, Baltimore, USA, 2016–2019
Fellowships & Special Training
- Fellowship — Hematology / Medical Oncology
- Fellowship — Stem Cell Transplantation & Cellular Therapy
- Training — Advanced CAR T-cell Therapy
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) Registration
- American Board of Internal Medicine (ABIM)
- Member — American Society of Hematology (ASH)
Areas of Expertise
Major Conditions Treated
- Acute Lymphoblastic Leukemia (B-ALL, T-ALL)
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Philadelphia-Positive ALL
- Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Aplastic Anemia
- Graft-Versus-Host Disease
Sub-specialties
- CAR T-cell Therapy for B-ALL: Co-investigator on Anti-CD19 CAR-T protocols for relapsed/refractory acute lymphoblastic leukemia — a leading acute leukemia specialist Riyadh, Saudi Arabia for international patients seeking cell therapy.
- Hematopoietic Stem Cell Transplantation: Performs matched-sibling, unrelated, and haploidentical adult HSCT with post-transplant cyclophosphamide protocols.
- CML in Pregnancy & Young Adults: Focused expertise in managing chronic myeloid leukemia during pregnancy using tailored tyrosine kinase inhibitor regimens and long-term maternal–fetal follow-up.
Advanced Procedures & Treatments
- Induction Chemotherapy for Acute Leukemia
- Tyrosine Kinase Inhibitor Therapy (Imatinib, Dasatinib, Ponatinib)
- Blinatumomab & Inotuzumab Ozogamicin for R/R B-ALL
- Autologous Stem Cell Transplant
- Allogeneic Stem Cell Transplant (Matched & Haplo-Identical)
- CD19 CAR T-cell Therapy
- Measurable Residual Disease (MRD) Monitoring
- Post-Transplant Cyclophosphamide Conditioning
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia — Consultant, Acute Leukemia Section, Department of Hematology, Stem Cell Transplantation and Cellular Therapy (Present)
Past Affiliations
- University of Maryland Medical Center, Baltimore, USA — Internal Medicine Resident, 2016–2019
- University of Texas MD Anderson Cancer Center, Houston, USA — Research / Fellowship experience in CAR-T and lymphoma HDC-ASCT
Academic & Research Roles
- Fellow — KFSHRC Hematology & Stem Cell Transplant Fellowship Programme
- Contributor — KFSHRC multi-center CML and Ph+ ALL registries
Key Achievements
- Co-author on multi-centre research on CD19 CAR-T in adult B-ALL
- Research on primary mediastinal large B-cell lymphoma treated with HDC-ASCT
- Contributor to 15-year single-centre CML-in-pregnancy cohort analysis
- Experience with international patients from the Gulf, Africa, and South Asia
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- American Board of Internal Medicine (ABIM)
- Saudi Society of Hematology
- Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT)
Research & Publications
Published Papers (Selected)
- Alzaidy N, Mohammed Saleh MF, Abdrabou A, Alasbali R, Bugnah A, …, Alkhaldi H, Alamer A, Saad A, …, Aljurf M, Alahmari A. Prognostic Impact of CD19 Status Pre-Lymphodepletion in Anti-CD19 CAR-T Therapy for B-Acute Lymphoblastic Leukemia. Blood. 2024;144(Suppl 1):7153.
- Alzaidy N, Ben Lamine C, Sharif MI, Hejab A, …, Alkhaldi H, …, Chaudhri NA. Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A 15-Year Single-Centre Study. Blood. 2024;144(Suppl 1):4536.
- Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 2023.
Ongoing Research & Clinical Interests
- Outcomes of CD19 CAR T-cell therapy in relapsed/refractory adult B-ALL
- Haploidentical transplantation for hematologic malignancies
- Inotuzumab ozogamicin and sinusoidal obstruction syndrome pre-transplant
- Management of CML during pregnancy
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Hematology Consultation | ₹1,500 – ₹3,500 | $18 – $42 |
| Bone Marrow Biopsy & Aspiration | ₹15,000 – ₹35,000 | $180 – $420 |
| Autologous Stem Cell Transplant | ₹15,00,000 – ₹22,00,000 | $18,000 – $26,500 |
| Allogeneic Stem Cell Transplant (Matched) | ₹22,00,000 – ₹35,00,000 | $26,500 – $42,000 |
| CAR T-cell Therapy | ₹1,50,00,000 – ₹3,50,00,000 | $1,80,000 – $4,20,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Hanan Alkhaldi use in Acute Leukemia treatment?
Dr. Hanan Alkhaldi uses modern hematologic tools including CD19 CAR T-cell therapy, blinatumomab, inotuzumab ozogamicin, haploidentical stem cell transplantation with post-transplant cyclophosphamide, and molecular MRD monitoring. For international patients, Cancer Rounds can coordinate a virtual pre-travel consultation to review bone-marrow reports and imaging.
2. What conditions does Dr. Hanan Alkhaldi specialize in treating?
Dr. Hanan Alkhaldi specialises in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Philadelphia-positive ALL, lymphomas eligible for autologous stem cell transplantation, and complex haematological malignancies requiring CAR-T or allogeneic transplant — making her a trusted acute leukemia specialist in Riyadh, Saudi Arabia for second opinions.
3. How do I book an appointment with Dr. Hanan Alkhaldi?
Appointments with Dr. Hanan Alkhaldi can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Hanan Alkhaldi?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Hanan Alkhaldi, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Hanan Alkhaldi offer second opinions for Acute Leukemia cases?
Yes. Second opinion consultations with Dr. Hanan Alkhaldi can be arranged via Cancer Rounds for patients seeking an expert Acute Leukemia review of diagnosis, risk-stratification, and stem-cell transplant or CAR-T eligibility.
